

1 **Multi-omics analysis in human retina uncovers ultraconserved *cis*-regulatory** 2 **elements at rare eye disease loci**

3

4 Victor Lopez Soriano^{*1,2}, Alfredo Dueñas Rey^{*1,2}, Rajarshi Mukherjee³, Genomics England Research
5 Consortium⁴, Frauke Coppieters^{1,2,5}, Miriam Bauwens^{1,2}, Andy Willaert^{1,2}, Elfride De Baere^{1,2}

6 1- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

7 2- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

8 3- Department of Ophthalmology, St James's University Hospital, Leeds, UK.

9 4- Genomics England, London, UK.

10 5- Department of Pharmaceutics, Ghent University, Ghent, Belgium.

11 *equal contribution

12 Corresponding author: Elfride De Baere (elfride.debaere@ugent.be)

13

14 **ABSTRACT**

15 Cross-species genome comparisons have revealed a substantial number of ultraconserved non-coding
16 elements (UCNEs). Several of these elements have proved to be essential tissue- and cell type-specific
17 *cis*-regulators of developmental gene expression. Here, we characterized a set of UCNEs as candidate
18 CREs (cCREs) during retinal development and evaluated the contribution of their genomic variation to
19 rare eye diseases, for which pathogenic non-coding variants are emerging. Integration of bulk and
20 single-cell retinal multi-omics data revealed 594 genes under potential *cis*-regulatory control of UCNEs,
21 of which 45 are implicated in rare eye disease. Mining of candidate *cis*-regulatory UCNEs in WGS data
22 derived from the rare eye disease cohort of Genomics England revealed 178 ultrarare variants within
23 84 UCNEs associated with 29 disease genes. Overall, we provide a comprehensive annotation of
24 ultraconserved non-coding regions acting as cCREs during retinal development which can be targets of
25 non-coding variation underlying rare eye diseases.

26 **KEYWORDS**

27 Ultraconserved non-coding elements (UCNEs), retina, single-cell, multi-omics, enhancer, *cis*-regulatory
28 elements (CREs), genomic variation, rare eye disease.

29

30 INTRODUCTION

31 The 'dark matter of the genome' harbors functional *cis*-regulatory elements (CREs) such as promoters,
32 enhancers, silencers, and insulators, whose orchestrated activity is essential to provide spatial and
33 temporal patterns of gene expression that ensure proper tissue development and homeostasis (Field
34 & Adelman, 2020; Spielmann & Mundlos, 2016). The influence of these regulatory elements on their
35 target genes spans within architectural chromatin units known as topologically associating domains
36 (TADs), demarcated by boundaries enriched in CTCF and cohesin proteins (Dixon et al., 2012). Due to
37 their high context specificity, the annotation of candidate CREs (cCREs) poses an attractive yet
38 challenging task. In this regard, the Encyclopedia of DNA Elements (ENCODE) (Abascal et al., 2020;
39 Dunham et al., 2012) represents a powerful tool to characterize functional cCREs, as it provides a
40 robust inventory of well-defined cCREs supported by epigenetic data derived from a wide variety of
41 both human tissues and cell types.

42 Over the past decades, comparative genomics have been made progress to map functional cCREs by
43 establishing cross-comparison between species. As a result, several databases of non-coding
44 sequences that exhibit extremely high conservation have been generated, including UCEs (Bejerano et
45 al., 2004; Lomonaco et al., 2014), UCNEs (Dimitrieva & Bucher, 2013), ANCORA (Engström et al., 2008)
46 and CONDOR (Woolfe et al., 2007). A direct comparison of these resources is, however, not
47 straightforward due to the intrinsic differences in the scopes of these databases. One of the most
48 comprehensive resources is UCNEbase, which comprises exclusively >200bp-long non-coding genomic
49 regions that exhibit $\geq 95\%$ sequence identity between human and chicken. The selection of these two
50 species was based on both biological and technical arguments, namely their considerable evolutionary
51 distance enhancing the accuracy in identifying functional elements, and the high-quality of their
52 respective genome assemblies. In total, 4,351 regions across the genome comply with the criteria and
53 are listed as ultraconserved non-coding elements (UCNEs) (Dimitrieva & Bucher, 2013). The vast
54 majority of these highly constrained elements cluster around key developmental genes, such as *PAX6*,

55 and have been long hypothesized to act as tissue-specific transcriptional regulators (Dimitrieva &
56 Bucher, 2013; Polychronopoulos et al., 2017). Ultraconserved CREs have been shown to be consistently
57 depleted of common variants (Drake et al., 2006; Snetkova, Ypsilanti, et al., 2021), indicating that
58 purifying selection has shifted ultraconserved CRE-derived allele frequencies towards magnitudes
59 similar to those observed for missense variants (Drake et al., 2006), hence reinforcing that variation
60 within these regions is more likely to have functional consequences.

61 Due to the wide implementation of whole genome sequencing (WGS) in human genetic studies and
62 ambitious initiatives such as the 100,000 Genome Project (100kGP) launched by Genomics England
63 (GEL) (Smedley et al., 2021), previously overlooked regions within the vast non-coding fraction of the
64 genome have been investigated in patients with rare diseases and have shown an emerging role of
65 non-coding variants in disease pathogenesis. Two remarkable examples of functional evidence of
66 disease driven by disruption of conserved CREs can be found precisely in the rare eye disease field, in
67 which mutations located within highly conserved non-coding regions have been linked to
68 developmental defects. A first example is a *de novo* single nucleotide variant (SNV) in an
69 ultraconserved enhancer (SIMO element) 150 kb downstream of an intact *PAX6* transcriptional unit,
70 found in a case with aniridia (Bhatia et al., 2013). Second, tandem duplications within a gene desert
71 downstream the *IRXA* cluster (Cipriani et al., 2017; Small et al., 2016) have been found in patients
72 affected by North Carolina Macular Dystrophy (NCMD); the shared duplicated region harbors an
73 enhancer element defined as UCNE that could act as a *cis*-regulator during retinal development (Van
74 de Sompele et al., 2022).

75 The retina is a heterogeneous tissue composed of neuronal (rod and cone photoreceptors, bipolar
76 cells, ganglion cells, horizontal cells, and amacrine cells) and non-neuronal cell types (astrocytes,
77 Müller cells and resident microglia) that arise from the common pool of retinal progenitor cells (RPCs)
78 (Turner et al., 1990; Turner & Cepko, 1988). This cellular complexity is the result of spatiotemporally
79 controlled gene expression programs during retinal development, requiring concerted action of
80 thousands of CREs (Lyu et al., 2021; X. Zhang et al., 2023). In the wide spectrum of retinopathies,

81 inherited retinal diseases (IRDs) represent a leading cause of early-onset vision impairment affecting
82 over 2 million people worldwide. Despite targeted panel-based sequencing and whole exome
83 sequencing (WES)-based genetic testing 30-50% of IRD cases remain unsolved (Ellingford et al., 2016;
84 Haer-Wigman et al., 2017), raising the hypothesis that disease-causing mutations are found in the non-
85 coding genome that are mostly not covered by standard genetic testing.

86 In this study we set out to annotate UCNEs as cCREs that modulate gene expression during retinal
87 development (Fig. 1A) and that can play a role in retinopathies such as IRDs. Firstly, we performed a
88 comprehensive integration of publicly available multi-omics datasets derived from human retina based
89 on biochemical features associated with regulation of gene expression. Secondly, UCNEs co-localizing
90 with genomic regions showing regulatory activity were linked to target genes that exhibit expression
91 in the retina. Finally, we evaluated the contribution of genomic variation within these regions to rare
92 eye diseases. This allowed us to identify an ultrarare SNV in a candidate *cis*-regulatory UCNE located
93 upstream *PAX6* in a family displaying autosomal dominant foveal abnormalities, for which we provide
94 functional evidence based on transgenic enhancer assays in zebrafish. Overall, this work has improved
95 the functional annotation of UCNEs in human retina representing understudied targets of non-coding
96 variation that may explain missing heritability in rare eye diseases.

97 **RESULTS**

98 **Integration of bulk and single-cell multi-omics data enables the identification of 1,487**

99 **UCNEs with a candidate *cis*-regulatory role in human retina**

100 The wealth of publicly available data allowed the integration of transcriptomic (bulk and scRNA-seq)
101 and epigenomic (DNase-seq, scATAC-seq, ChIP-seq) data to evaluate the regulatory capacity of UCNEs
102 over the major developmental stages of human retina. More specifically, to identify which UCNEs
103 might have a potential *cis*-regulatory role, an intersection was performed with genomic regions
104 characterized by an open chromatin context in the retina at different developmental stages, as
105 supported either by DNase (ENCODE) or scATAC-seq (Thomas et al., 2022) peaks. This resulted in a

106 total of 1,487 UCNEs, i.e., approximately one third of UCNEs display a retinal open context (Fig. 1B,
 107 Supplementary Table 1) (hereinafter referred to as putatively active UCNEs). Approximately 80% of the
 108 DNase-seq peaks were also supported by scATAC-seq, hence defining high-confidence candidate *cis*-
 109 regulatory UCNEs (Fig. 1B). Nevertheless, to account for differences in time points between datasets,
 110 all 1,487 UCNEs were included in downstream analyses. Apart from the display of a retinal open
 111 chromatin context, we also evaluated the overlap between UCNEs and genomic regions featured by
 112 markers associated with regulation of gene expression. A total of 834 UCNEs were found to display at
 113 least one of the assessed features in the interrogated retinal developmental stages; more specifically
 114 111 UCNEs were identified to display the active enhancer mark H3K27ac, of which most (95%) also
 115 exhibit other histone marks related to active enhancers (H3K4me1 and H3K4me2) (Fig. 1B). Out of
 116 these 111 UCNEs, 33 were found to maintain signatures consistent with enhancer activity (H3K27Ac)
 117 at adult stage. Table 1 and Supplementary Tables 1,2 include summarized and detailed overviews of
 118 the number of identified UCNEs per marker and stage, respectively.

119 **Table 1. Overview of the number of events based on the peak identification for each marker at the**
 120 **different stages of retinal differentiation.** Abbreviations: FW: fetal weeks.

	Stage					Total Unique
ChIP-seq	FW13/14	FW15/16	FW18/20	FW23/24		
H3K27ac	73	45	74	94	127	
H3K4me1	235	490	48	323	582	
H3K4me2	347	354	256	225	465	
H3K4me3	94	124	102	97	136	
H3K27me3	119	54	128	126	154	
H3K9/14Ac	51	76	36	31	94	
H3K9me3	0	1	1	29	29	
Pol II	17	66	59	55	106	
CTCF	51	69	22	37	71	

129 To investigate the functional relevance of the putative regulatory UCNEs, we performed a correlation
 130 with the 1,942 experimentally validated human non-coding fragments of the VISTA Enhancer Browser
 131 (Fig. 1C). Out of these 1,942 elements, approximately 50% (998/1,942) display enhancer activity. When
 132 overlapped with all 4,135 UCNEs, a slight increase of positive elements (505/922) is observed;

133 however, when only the identified retinal accessible UCNEs were considered, roughly 68% were found
134 to be positive (272/402), thereby reinforcing their predicted regulatory role (Fig. 1C). Interestingly,
135 evaluation of the anatomical description of the reporter gene expression patterns of these 272
136 elements revealed a potential enrichment in eye (Fig. 1D). An illustrative example of one of these
137 elements and its corresponding multi-omics-based characterization is shown in Fig. 1E-F.

138 ***In silico* prediction and integration of retinal chromatin conformation data identify putative** 139 **target genes under UCNE *cis*-regulation**

140 We made use of the *GREAT* algorithm to assign potential target genes to the identified putatively active
141 UCNEs and thus assess their association with genes expressed in the retina (Granja et al., 2021). A total
142 of 724 target genes were assigned to the initially identified 1,487 UCNEs displaying candidate *cis*-
143 regulatory activity. The vast majority (74.5%) of queried regions were assigned as putatively regulating
144 two genes based on the used association rule (Fig. 2A). Furthermore, most of these regions were found
145 to be located at 50-500kb from the TSS of the regulated target genes regardless of their orientation
146 (Fig. 2B). Out of these 724 target genes, 594 (81.9%) are expressed in the retina in at least one of the
147 interrogated developmental stages (52 to 136 days post-conception). To evaluate further whether
148 chromatin contacts between the UCNEs and the promoters of their target genes can occur in retina,
149 we integrated the 2,948 retinal TADs identified by Marchal et al. (Marchal et al., 2022). A large majority
150 (393/594) of the target genes were found to be in TADs also harboring their associated UCNE
151 (Supplementary Table 1). These genes were then used as input for Gene Ontology analysis, which
152 revealed an overrepresentation of terms related to regulation of transcription and differentiation,
153 thereby confirming the expected roles of UCNEs as tissue-specific CREs during development,
154 particularly of the nervous system (Fig. 2C; Supplementary Table 3).

155 As a last layer of characterization of these putatively active UCNEs and their candidate target genes,
156 we assigned to each target gene cell-type specificity information based on expression data. Out of the
157 1,487 putatively active UCNEs, 808 (54.3%) displayed a cell-type specific open chromatin context

158 consistent with their target gene(s) expression signature(s) (Supplementary Table 1). Furthermore, we
159 evaluated the overlap between the sets of target genes assigned to UCNEs by *GREAT* followed by gene
160 expression filtering and those mapped by implementing the peak-to-gene linkage method on the
161 scATAC-seq data. Although a substantial number of target genes overlapped between both methods
162 (Supplementary Table 4), it is noteworthy to mention that almost half of the UCNEs were assigned to
163 different target genes, most likely due to differences in the annotations employed by both methods.

164 **Mining of WGS data from a rare eye disease cohort reveals rare variants within putatively** 165 **active UCNEs**

166 Out of the 594 putative target genes under UCNE *cis*-regulation, 45 were found to be previously linked
167 to a rare eye disease phenotype, of which 23 are IRD genes and 19 are also associated with other
168 developmental disorder phenotypes (Supplementary Table 5). Considering the extreme selective
169 constraints of UCNEs, we hypothesized that genetic changes in these regions could contribute to
170 disease. Therefore, we evaluated the genomic variation within the putatively active UCNEs associated
171 with these 45 disease genes in a sub-cohort of individuals affected by rare eye diseases ($n = 3,220$,
172 Supplementary Table 6) from the 100,000 Genomes Project (Fig. 3A).

173 As expected, a depletion of common variation ($MAF > 1\%$) was observed across these regions (Fig. 3B).
174 This depletion was found to be not only restricted to the examined sub-cohort but rather constitutes
175 a more general phenomenon. In particular, UCNEs were found to exhibit significantly lower genome-
176 wide residual variation intolerance score (gwRVIS) (Vitsios et al., 2021) values compared to a set of
177 randomly selected genomic regions, thereby reflecting their high intolerance to genomic variation (Fig.
178 3C).

179 A total of 431 (426 SNVs and 5 SVs) ultrarare variants, i.e., absent from reference population public
180 databases, were identified in 199 putatively active UCNEs linked to these 45 genes (Supplementary
181 Table 7). Additionally, we computed the allele frequency distribution of all variants retrieved within a
182 selection of 25 of these disease genes and compared it against that of their corresponding UCNE. As

183 before, a distinct depletion of common variation was observed, thereby further supporting the
184 specificity of the overlap of (ultra-)rare variants and UCNEs (Fig. S2).

185 Notably, out of the 5 identified SVs, one corresponds to the known shared duplicated region
186 downstream of *IRX1*, located within the NCMD-linked *MCDR3* locus [MIM: 608850]; in particular, this
187 duplication, identified in 8 affected individuals of 4 different families segregating macular defects
188 consistent with NCMD, involves a UCNE (*IRXA_Aladdin*) exhibiting chromatin accessibility in developing
189 horizontal cells. Finally, out of these ultrarare variants, 178 are located within 84 UCNEs displaying
190 histone modification marks (in at least one of the interrogated stages), associated with 29 genes. This
191 set defined our primary search space for variants with potential functional effects and further
192 assessment.

193 **An ultrarare SNV in an active UCNE upstream of *PAX6* found in a family segregating** 194 **autosomal dominant foveal anomalies**

195 We identified an ultrarare SNV (chr11:31968001T>C) within a candidate *cis*-regulatory UCNE located
196 ~150kb upstream of *PAX6* (*PAX6_Veronica*). This variant was found in four individuals of a family
197 segregating autosomal dominant foveal abnormalities (Fig. S3A-B; Supplementary Table 8). A *CFH*
198 missense variant (c.1187A>G, p.Asn396Ser) was initially reported in the affected individuals but could
199 not explain the foveal anomaly. Given the phenotype, a variant screening was performed with a
200 particular focus on the *PRDM13* and *IRX1* NCMD loci, both associated with foveal or macular mis-
201 development. A total of three and two SNVs within the *IRX1* and *PRDM13* loci respectively were found
202 to segregate with disease. However, these SNVs are present in individuals from reference population
203 databases and are not located in genomic regions displaying *cis*-regulatory features (Supplementary
204 Table 9). Equally, loci associated with foveal hypoplasia, nystagmus and hypopigmentation (*AHR*,
205 *FRMD7*, *GPR143*, and *SLC38A8*) were assessed for SNV or SV segregating with disease. No other (likely)
206 pathogenic variants in these loci or any other known IRD/rare eye disease gene were identified in the
207 affected cases (Supplementary Table 9).

208 The identified chr11:31968001T>C variant affects a nucleotide residue that is conserved for at least
209 360 million years of evolution that separate humans from *X. tropicalis*. *In silico* assessment of this
210 variant and flanking sequence pointed to a likely deleterious effect and revealed a predicted disruption
211 of several TF binding motifs (Supplementary Table 9). More specifically, this variant is located within a
212 UCNE (*PAX6_Veronica*) that is catalogued as a cCRE in ENCODE (EH38E1530321), featured by distal
213 enhancer-like signatures in bipolar neurons. Regarding its retinal context, this UCNE displays accessible
214 chromatin in the early stages of retinal development (7/8 gestational weeks), and in particular in
215 ganglion cell precursors (Fig. 4A-B). Importantly *PAX6* is expressed within this pool of cells and,
216 interestingly, this expression appears to be enriched within a specific sub-population, as observed from
217 the distribution of expression values across all the cells composing this cluster (Fig. S4). Additionally,
218 this UCNE was found to display the active enhancer mark H3K4Me1 at the earliest time points available
219 for this dataset (13/14 and 15/16 gestational weeks).

220 This region has also been functionally validated in transgenic mouse assays (VISTA element hs855),
221 which revealed gene enhancer activity mainly in the forebrain and, to some extent, in the retina (3/6
222 embryos) (Fig. 5A). A closer assessment of this UCNE with regard to its proximity to the *PAX6* promoter
223 in other species revealed its syntenic conservation up to zebrafish; interestingly, this element localized
224 in closer proximity to the *PAX6* promoter in species like *X. tropicalis* (60kb distance from the TSS) or
225 *Danio rerio* (15kb distance from the *pax6a* TSS) (Fig. S5).

226 ***In vivo* enhancer assays in zebrafish support the association between candidate *cis*-** 227 **regulatory UCNE and *PAX6***

228 Given the putative retinal activity suggested by the VISTA enhancer assay for this UCNE, we performed
229 zebrafish enhancer assays to gain further insights into its regulatory range of action. We found
230 consistent reporter expression in several regions, including the forebrain, hypothalamus/otic vesicle,
231 somites, nosepit and eye. Importantly, we observed that the GFP expression in the eye initiated in a
232 small fraction of the embryos at 2 dpf (4/22 GFP⁺ embryos) increasing to a larger proportion of the

233 embryos by 3 dpf (21/22 GFP⁺ embryos) and eventually disappeared from 4 dpf (Fig. 5B). Altogether,
234 these observations are consistent with the epigenomic characterization based on retinal datasets and
235 provides further evidence of a potential *cis*-regulatory role of this UCNE on *PAX6* expression. Using the
236 same setting, we also evaluated the reported expression activity the mutated version of this UCNE,
237 i.e., harboring the SNV identified in the affected individuals of the family described before. However,
238 no conclusive differences were observed with respect to the wild-type version. A detailed overview of
239 the results of these assays can be found in Supplementary Table 10.

240 **DISCUSSION**

241 Since the landmark study of Bejerano et al. (Bejerano et al., 2004) almost twenty years ago,
242 ultraconservation of non-coding elements and their paradoxical functional (in)dispensability (Ahituv et
243 al., 2007; Chiang et al., 2008; Dickel et al., 2018; Drake et al., 2006; Snetkova, Pennacchio, et al., 2021)
244 have equally stirred controversy and fascination among scientists from diverse disciplines. A recent
245 study demonstrated that UCNEs with robust enhancer activity during embryonic development appear
246 to be unexpectedly resilient to mutation (Snetkova, Pennacchio, et al., 2021). There are, however, clear
247 instances in which variation within ultraconserved CREs can be a driver of human rare disease (Benko
248 et al., 2009; Bhatia et al., 2013; Ghasvand et al., 2011; Klopocki et al., 2008; Kvon et al., 2020; Lettice
249 et al., 2003; Martínez et al., 2010; Plaisancié et al., 2018; Wieczorek et al., 2010). Despite the
250 substantial body of literature on these intriguing elements, thus far there are no comprehensive
251 studies based on the integration of multi-omics to map the regulatory capacity of UCNEs in a specific
252 tissue or cells, and on human genetic data to assess their contribution to disease. Apart from a few
253 well-known examples, variants in CREs are an underrepresented cause of Mendelian diseases. A major
254 obstacle hampering their identification is the need to define the search space of the CREs they affect
255 in a tissue- and even cell-type specific manner. Here we set out to address this challenge in human
256 retina, of which the *cis*-regulatory architecture has been well-studied (Cherry et al., 2020; Marchal et

257 al., 2022; Thomas et al., 2022) and for which there is emerging *cis*-regulatory variation implicated in
258 disease (Bhatia et al., 2013; Ghiasvand et al., 2011; Plaisancié et al., 2018; Van de Sompele et al., 2022).
259 Although ENCODE provides a well-annotated inventory of cCREs, its retinal datasets do not include the
260 earliest stages of RPC differentiation. To overcome this and to incorporate cell-type specificity
261 information, we integrated scATAC-seq, which allowed us to identify 1,487 UCNEs characterized by
262 accessible chromatin in at least one major stage of retinal development. We also interrogated the
263 epigenetic landscape of these elements by analyzing histone modification patterns associated with e.g.
264 active/poised enhancers (H3K27ac, H3K4me1, H3K4me2) (Creyghton et al., 2010; Rada-Iglesias et al.,
265 2011; Santos-Rosa et al., 2002) and highly packed chromatin (H3K27me2 and H3K27me3) (Juan et al.,
266 2016). This analysis provided a useful approach to trace the activity of elements that are active at a
267 specific stage during retinal development. In total, 111 UCNEs were found to display active enhancer
268 marks during retinal development. Similarly to ENCODE, the analyzed ChIP-seq datasets do not cover
269 the earliest stages and hence these 111 elements are more likely to be related to stages of
270 differentiation corresponding to later-born cell types (i.e., rod photoreceptors, bipolar cells, Müller
271 glial, and some varieties of amacrine cells) (Rapaport et al., 2004). Interestingly, of these 111 elements,
272 33 were found to exhibit sustained enhancer-related signatures in adult stage, suggesting their
273 potential role in the maintenance of gene expression patterns after development. Overall, our data
274 integration spans all the major stages of retinogenesis and thus provides a comprehensive framework
275 for the systematic characterization of ultraconserved retinal CREs.
276 Establishing an association between cCREs and their putative target genes is essential for the
277 interpretation of genomic variation that could disrupt cell type-specific binding sites of TFs and/or long-
278 range chromatin contacts that can lead to ectopic expression of genes (de Bruijn et al., 2020; Lupiáñez
279 et al., 2015). Here we combined *GREAT* (McLean et al., 2010) with retinal expression and Hi-C derived
280 retinal data to assign a range of action to candidate *cis*-regulatory UCNEs. We found this procedure to
281 be more comprehensive than assigning target genes only based on the correlation provided by the
282 peak-to-gene linkage method we used (Granja et al., 2021). In total, 594 retina-expressed genes can

283 be under UCNE *cis*-regulation; interestingly most of the UCNEs were found to be distributed in distal
284 position from the TSS of their assigned target genes, as observed for enhancers promoting expression
285 of developmental genes (Benko et al., 2009; Long et al., 2020; Pachano et al., 2022). In this regard, a
286 large fraction of the identified ultraconserved putative enhancers clusters around key developmental
287 genes (e.g. *MAB21L2*, *OTX2*, *PAX6*, *SOX2*, *ZEB2*) known to be controlled by complex regulatory
288 landscapes (Polychronopoulos et al., 2017). Besides, 45 of these genes are implicated in rare eye
289 diseases. Interestingly, coding variants in these genes lead in most cases to syndromic developmental
290 phenotypes with other manifestations apart from the ocular ones as collated in the G2P database ²³.
291 As it has been shown before, the phenotype caused by a coding mutation of a developmental gene
292 can be different from the phenotype caused by a mutation in a CRE controlling spatiotemporal
293 expression of this gene; this is exemplified by the *PRDM13* locus, for which bi-allelic coding *PRDM13*
294 variants result in hypogonadotropic hypogonadism and perinatal brainstem dysfunction in
295 combination with cerebellar hypoplasia (Whittaker et al., 2021) while *cis*-regulatory variants in retinal
296 CREs leads to NCMD, a developmental macular disease (Van de Sompele et al., 2022). From our
297 analyses we could identify a cCRE for *PRDM13* (*PRDM13_Blooklyn*) that displays an open chromatin
298 context in early RPCs and developing amacrine cells, which are precisely the retinal cell types in which
299 *PRDM13* is expressed (Goodson et al., 2018; Watanabe et al., 2015). Although no disease associations
300 have been established thus far for other genes for which we identified candidate *cis*-regulatory UCNEs,
301 some of them are known to play important roles in retina development, e.g., *NFIB* (Clark et al., 2019),
302 and therefore represent potential target regions for non-coding variants contributing to missing
303 heritability.

304 A limitation of this analysis is the usage of a pre-defined set of genomic regions, in particular UCNEs,
305 as this database is static and rarely updated (Polychronopoulos et al., 2017). Our approach could thus
306 be expanded using more flexible criteria, thus including other less conserved, albeit disease-relevant
307 loci (Ghiasvand et al., 2011). Nonetheless, the advantage of working with highly conserved genomic
308 regions is the availability of already validated experimental data (Visel et al., 2007); additionally, as

309 shown here, the integration of tissue-specific epigenomic data provides a robust framework to identify
310 potential *bona fide* enhancers and their corresponding target genes, and clinically relevant variants
311 therein.

312 To further investigate the contribution of genomic variation within candidate *cis*-regulatory UCNEs to
313 disease, we mined WGS data from a sub-cohort of 100,000 Genome Project Genomics England
314 participants affected by different rare eye diseases. As reported previously (Katzman et al., 2007;
315 Snetkova, Pennacchio, et al., 2021), we observed a substantial depletion of common variation across
316 these regions when compared to a background comprising randomly selected genomic regions.
317 Indeed, intolerance to variation was also found to extend to the regions flanking the ones strictly
318 defined as UCNEs. This apparently strong purifying selection has been proven difficult to reconcile with
319 recent findings demonstrating remarkable resilience of UCNEs to variation (Snetkova, Ypsilanti, et al.,
320 2021). Moreover, it has been suggested that weaker but uniform levels of purifying selection across
321 hundreds of bases and different species could bring together these otherwise contradictory
322 observations and explain why rare variants are not significantly depleted within UCNEs (Dukler et al.,
323 2022). Our primary search space for variants with potential functional effects comprised 178 ultrarare
324 variants located within 84 putatively active UCNEs associated with 29 genes. Interestingly, most of
325 them were predicted to have a likely functional and/or deleterious effect, which could be explained by
326 a skewed cumulative importance towards evolutionary conservation-related features in the predictive
327 models (Rogers et al., 2018; Schwarz et al., 2019; Shi et al., 2021; Zhou & Troyanskaya, 2015).

328 Out of all variants found, one ultrarare variant (chr11:31968001T>C) within a UCNE displaying open
329 chromatin in progenitor ganglion cells and linked to *PAX6* was further dissected. This variant was
330 exclusively found within the studied family, displaying isolated foveal abnormalities, and initially solved
331 with an ultrarare missense variant in *CFH*, which could not fully explain the clinical presentation
332 (Raychaudhuri et al., 2011; Taylor et al., 2019). As no other likely pathogenic variants were found
333 within relevant loci (Ehrenberg et al., 2021; Kuht et al., 2020, 2022; Small et al., 2016; Van de Sompele
334 et al., 2022), and the observed phenotypes of the affected individuals match within the *PAX6* disease

335 spectrum, mis-regulation of *PAX6* expression cannot be excluded as a pathogenetic mechanism.
336 Genetic defects of *PAX6* have been found in aniridia, a pan-ocular disorder characterized by the
337 absence or hypoplasia of the iris, nystagmus and foveal hypoplasia (Cunha et al., 2019), the latter
338 comprising thinning of macular inner and outer retinal layers consistent with misdirected foveal
339 development (Pedersen et al., 2020). Recently, a phenotype characterized by isolated foveal
340 hypoplasia with nystagmus has been also linked to *PAX6* variation (Lima Cunha et al., 2021). Given the
341 known inter- and intra-familial phenotypic variability observed in *PAX6*-associated disorders (Dubey et
342 al., 2015; Yokoi et al., 2016), variable expressivity cannot be discarded for the identified variant. Thus
343 far, in terms of regulatory variation in CREs, only a single SNV located within the ultraconserved SIMO
344 element has been associated with *PAX6*-disease. This subtle change (SNV), identified *de novo* in an
345 individual with aniridia and foveal hypoplasia, was found to disrupt an autoregulatory *PAX6* binding
346 site (Bhatia et al., 2013). Importantly, we could establish *in vivo*, using the zebrafish as animal model,
347 a developmental expression pattern in the eye driven by this UCNE in tissues for which *PAX6* expression
348 is relevant (Ashery-Padan et al., 2000; Collinson et al., 2003; Georgala et al., 2011; Kimura et al., 2005;
349 Pituello et al., 1999) and within a time window consistent with the period in which the zebrafish retina
350 has become fully laminated (Morris & Fadool, 2005; Schmitt & Dowling, 1999). We could not obtain
351 conclusive functional results for the identified variant using our experimental approach. A major
352 limitation of this setting is the fact that the UCNE and its mutant version were tested outside of their
353 native genomic context. Therefore, to validate the role of this UCNE in *PAX6* regulation, further
354 functional assays that consider the native context, such as CRISPRi (Larson et al., 2013), are needed.
355 Studying the molecular consequences of the variant itself in a patient-derived cellular model, however,
356 is more challenging, since currently no models, including patient-derived retinal organoids, fully
357 recapitulate foveal patterning (Hussey et al., 2022).

358 Overall, our work is exemplar for how the wealth of publicly available multi-omics data can be used to
359 exploit the regulatory capacity of UCNEs in a tissue- and cell type-specific way. As demonstrated here,
360 UCNEs can represent understudied regions of non-coding variation underlying missing heritability in

361 Mendelian diseases. With the increasing implementation of WGS in rare disease research and
362 diagnosis, the delineation of tissue and cell type-specific CREs will be a prerequisite to identify and fully
363 interpret the pathogenic nature of non-coding variants. With this study, we have illustrated how the
364 creation of a comprehensive set of functionally annotated UCNEs in a target tissue can represent a
365 powerful initial strategy to narrow down the variant search space, particularly for developmental
366 phenotypes.

367 **METHODS**

368 **Integration of UCNEs with bulk and single-cell epigenomic, regulatory and transcriptional** 369 **datasets from human developing and adult retina**

370 The 4,351 genomic regions defined as UCNEs (Dimitrieva & Bucher, 2013) were used as the basis for
371 the integration of multiple publicly available multi-omics datasets derived from embryonic and adult
372 human retina. More specifically, to evaluate the potential function of UCNEs as *cis*-regulatory modules,
373 we made use of DNase-seq (Abascal et al., 2020), ChIP-seq of histone modifications (Aldiri et al., 2017;
374 Cherry et al., 2020), and single-cell (sc) ATAC-seq (Thomas et al., 2022) derived from retinal tissue
375 collected at distinct stages of development. Furthermore, to correlate potential *cis*-regulatory activity
376 with gene expression, we mined both bulk (Hoshino et al., 2017) and scRNA-seq (Thomas et al., 2022)
377 generated at stages overlapping or extending the ones of the epigenomic datasets. Additionally, as a
378 last layer of functional characterization, we integrated into our analyses the experimental data of the
379 VISTA Enhancer Browser (Visel et al., 2007), which allows the classification of candidate regulatory
380 elements based on *in vivo* enhancer reporter assays tested in transgenic mice at embryonic day 11.5
381 (Pennacchio et al., 2006). Supplementary Table 11 provides an overview of all used datasets.

382 **Identification of candidate *cis*-regulatory UCNEs in retina**

383 Data generated by scATAC-seq of embryonic (53, 59, 74, 78, 113, and 132 days) and adult (25, 50, and
384 54 years old) human retinal cells were obtained (GSE183684) and imported into R (v4.0.5). Count

385 matrices were processed using the *ArchR* single-cell analysis package (v1.0.1) (Granja et al., 2021) as
386 described in Thomas et al., 2022(Thomas et al., 2022) with minor modifications. Briefly, the total
387 number of cells after filtering out doublets was 61,313. Single-nucleus RNA-seq of the same tissue and
388 timepoints (GSE183684) were integrated using the unconstrained integration method so as to
389 establish a linkage between the scATAC-seq and scRNA-seq datasets. More specifically, the
390 unconstrained integration is a completely agnostic approach considering all cells derived from an
391 scATAC-seq experiment and attempting to align them to any cells in the respective scRNA-seq
392 experiment (Granja et al., 2021).

393 Both datasets were then used to assign retinal cell class identities to the different clusters based on
394 known markers (Thomas et al., 2022) and subsequent peak calling. BigWig files from each annotated
395 cell cluster were extracted and converted into bedGraph files using *bigWigtoBedGraph* UCSC utility;
396 narrow peak detection was performed using *bdgpeakcall* (MACS2.2.7.1) (Y. Zhang et al., 2008) with
397 default parameters and a value of 0.4 as cut-off (median peak width: 300bp). Similarly, bigWig files
398 corresponding to histone modification patterns (H3K27Ac, H3K27me3, H3K36me3, H3K4me1,
399 H3K4me2, H3K4me3, H3K9/14Ac, H3K9me3, PolII, CTCF) were retrieved (GSE87064) and converted
400 into bedGraph files; in this case, the cut-off value for peak calling by *bdgpeakcall* was set at 20.
401 Additionally, the subset of ENCODE DNase hypersensitivity sites (rDHSs) identified in embryonic retina
402 (74-85, 89, 103-125 days) were obtained (ENCSR786VSQ, ENCSR666FML, ENCSR632UXV; median peak
403 width: 300bp) and elements featured by *Low-DNase* filtered out.

404 Finally, to identify putative *cis*-regulatory UCNEs, we screened for overlaps between UCNEs and the
405 retrieved sc-ATAC/ChIP/DNase-seq peaks using *bedtools intersect* (*BEDTools* v2.30.0)(Quinlan & Hall,
406 2010) with default parameters; of note *bedtools window* including a ± 250 bp-long window was used
407 when overlapping the ChIP-seq peaks to characterize more broadly the chromatin status in the vicinity
408 of the accessible UCNEs (Fig. S6).

409 **Identification and characterization of target genes under putatively active UCNE regulation**

410 To assign potential target genes to the identified active UCNEs we used the Genomic Regions
411 Enrichment of Annotations Tool (*GREAT*) (McLean et al., 2010) (v4.0.4). Briefly, this tool computes
412 statistics by associating genomic regions with nearby genes and applying the gene annotations to the
413 regions. More specifically, when run against a whole genome background, two statistical tests are
414 performed, namely the binomial test over genomic regions and the hypergeometric test over genes,
415 thereby providing comprehensive annotation enrichments for the input genomic regions. Here, *GREAT*
416 was run using an association rule based on the definition of an extended basal regulatory domain. Each
417 gene in the genome was assigned a basal regulatory domain (5kb and 1kb upstream and downstream
418 of the transcription start site {TSS}, respectively) with an extension of up to 1Mb to the nearest gene's
419 basal domain. Each putatively active UCNE was then associated with all genes whose regulatory region
420 it overlapped. In addition, curated regulatory domains were also included. These domain are
421 supported by experimental evidence demonstrating that a gene is directly regulated by an element
422 located beyond of its putative regulatory domain. In particular, for the utilized version of *GREAT*, these
423 domains included the Sonic hedgehog long-range enhancer, the *HOXD* global control region, and the
424 Beta-globin locus control region (McLean et al., 2010).

425 Potential target genes were subsequently filtered based on retinal expression. To do so, we retrieved
426 RNA-seq paired-end FASTQ files derived from fetal retina samples (52 to 136 days post-conception)
427 characterized in Hoshino et al. (Hoshino et al., 2017). Transcripts were quantified through pseudo-
428 alignment by *Kallisto* (v.0.46.1)(Bray et al., 2016) using default parameters for both index build (derived
429 from the Ensembl human release 101) and transcript abundance estimation. Transcript estimates were
430 imported and summarized to create gene-level count matrices using *tximport* (v3.17) (Soneson et al.,
431 2016). A custom script was then used to filter out target genes exhibiting no expression (TPM<0.5) at
432 any of the interrogated stages. Additionally, to evaluate the reliability of the regulatory domains
433 assigned by *GREAT* to these target genes, we integrated the 2,948 retinal TADs described by Marchal
434 et al. (Marchal et al., 2022). To characterize further the putatively regulated target genes, we made
435 use of the integration of the scATAC-seq gene scores and the scRNA-seq gene expression matrices

436 generated by *ArchR*. In particular, a gene score is a prediction of how highly expressed a gene will be
437 based on the accessibility of nearby regulatory elements (Granja et al., 2021). For each target gene, its
438 expression was ranked by percentile of expression across all clusters. A gene expression signature was
439 then assigned by retrieving the cluster identities exhibiting an expression value above the 80th
440 percentile threshold.

441 In addition, we compared the sets of target genes assigned to UCNEs by *GREAT* and subsequent gene
442 expression filtering, to those mapped using the peak-to-gene linkage method implemented by *ArchR*.
443 To do so, scATAC-seq data peaks that had a Peak2GeneLinkage correlation above 0.4 and their
444 corresponding target genes were kept. UCNEs were then assigned to these peaks by *bedtools intersect*
445 as described above, including a ± 250 bp-long window. The overlap between predicted target genes was
446 computed with respect to those assigned by *GREAT*.

447 Finally, to identify overrepresented Gene Ontology (GO) terms and infer possible enriched pathways
448 among the potential target genes under UCNE regulation, GO enrichment analyses were performed
449 using *Enrichr* (Xie et al., 2021).

450 **Interrogation of WGS data in a rare eye disease cohort**

451 Putatively active UCNEs associated with genes expressed in retina were filtered further based on their
452 implication in disease as retrieved from the comprehensive *gene-disease pairs and attributes* list
453 provided by G2P (Eye and Developmental Disease –DD– Panels; 2022-03-17) (Lenassi et al., 2021;
454 Thormann et al., 2019) extended with the NCMD-associated *IRX1* locus (Small et al., 2016). To assess
455 the contribution of genomic variation within these loci to disease, an analysis was performed to detect
456 small variants (SNVs, and indels < 50bp), and large structural variants (SVs) including copy number
457 variants (CNVs) overlapping these disease-gene associated UCNE loci through query of a sub-cohort of
458 participants with rare eye disease phenotypes (n = 3,220) from the 100,000 Genomes Project (100KGP,
459 Genomics England).

460 Retrieved variants were annotated with VEP (v.107). As a first filter, only variants with minor allele
461 frequency (MAF) <0.5% and no observed homozygotes in gnomAD v3.1 were considered for further
462 assessment. Variants were evaluated for their potential pathogenic/modifying effect using *in silico*
463 prediction tools focusing on transcription factor (TF) binding site disruption -*QBiC-Pred*- and chromatin
464 state effects -*DeepSea*, *CARMEN*, *FATHMM-XF*, *RegulationSpotter*- under default parameters (V.
465 Martin et al., 2019; Rogers et al., 2018; Schwarz et al., 2019; Shi et al., 2021; Zhou & Troyanskaya,
466 2015). Furthermore, we annotated these variants with our integrated analyses in order to evaluate
467 them within their regulatory context and potential target genes.

468 For each candidate variant, we compared the similarities between the participant phenotype (HPO
469 terms) and the ones known for its target gene through literature search and clinical assessment by the
470 recruiting clinician when possible. Finally, for each candidate variant identified in participants whose
471 cases were not solved through 100KGP, a variant screening of 387 genes listed in either the Retinal
472 disorders panel (v2.195) from Genomics England PanelApp (A. R. Martin et al., 2019) or RetNet
473 (<https://sph.uth.edu/retnet/>) was performed to discard (likely) pathogenic variants, both SNVs and
474 SVs, that could provide an alternative molecular diagnosis. For each instance for which only the UCNE
475 variant remained as candidate, we placed a clinical collaboration request with Genomics England.

476 **Evaluation of allele frequency distribution within UCNEs**

477 Allele frequency distributions were created for the set of variants retrieved within disease-gene
478 associated UCNE loci and compared against the distribution derived from a background composed of
479 200 random genomic sequences. This background was generated using the *random-genome-*
480 *fragments* utility of Regulatory Sequence Analysis Tools (*RSAT*) with a fixed length of 350bp (Santana-
481 Garcia et al., 2022). Importantly, *GREAT* was used to evaluate the distribution of distances of the
482 randomly selected regions to the TSS of genes to ensure no confounding effects in the downstream
483 analyses. Indeed, no significant differences were observed in such distribution as compared to that of
484 the UCNEs (Fig. S1). Moreover, no GO terms were overrepresented among the target genes assigned

485 to these random genomic regions, thereby further supporting the suitability of this background for the
486 analysis.

487 To evaluate whether the depletion of common variation within UCNEs is a more general phenomenon,
488 we made use of genome-wide residual variation intolerance scores (gWRVIS), a nucleotide-resolution
489 metric that quantifies genomic constraint. As such, lower gWRVIS values correspond to greater
490 intolerance to variation (Vitsios et al., 2021). We downloaded gWRVIS data (hg38-build, v1.1) for all
491 chromosomes and queried it for the regions of interest using *tabix* (v1.7.2) (H. Li, 2011). More
492 specifically, these regions included: disease-gene associated UCNE loci, a flanking region encompassing
493 200bp up- and downstream of each of these UCNEs, and the 200 random genomic sequences
494 described above. Two-sided Mann–Whitney U tests were used to compare the gWRVIS distributions
495 across all pairs.

496 Additionally, in order to assess the specificity of the overlap of rare variants in the studied patient sub-
497 cohort with UCNEs, we generated allele frequency distributions corresponding to all variants retrieved
498 for a selection of 25 target disease gene loci under putative UCNE regulation and their corresponding
499 UCNEs. For each disease-gene and UCNE pair, we plotted the proportion of ultra-rare (absent from
500 gnomAD v3.1), very rare (MAF < 0.1%), rare ($0.1\% \leq \text{MAF} < 0.5\%$), low frequency ($0.5\% \leq \text{MAF} < 5\%$),
501 and common ($\text{MAF} \geq 5\%$) variants.

502 **Targeted sequencing and reverse phenotyping**

503 We performed segregation testing of two ultrarare SNVs initially identified in three affected individuals
504 of a 3-generation family displaying autosomal dominant foveal abnormalities, namely an SNV in a
505 candidate *cis*-regulatory UCNE located upstream of *PAX6* and a missense *CFH* variant. Genomic DNA
506 was extracted using Oragene-DNA saliva kits (OG-500, DNA Genotek) according to manufacturer's
507 instructions. Targeted sequencing of the variants was performed on genomic DNA by PCR amplification
508 followed by Sanger sequencing using the BigDye Terminator v3.1 kit (Life Technologies). Primer
509 sequences can be found in Supplementary Table 12.

510 Following their genetic assessment, four members of this 3-generation family were clinically re-
511 evaluated. The examination included visual acuity assessment, slit-lamp examination for anterior and
512 posterior segment anomalies, and intraocular pressure measurement. Detailed imaging involving
513 ultra-wide field fundus photography, ultra-wide field autofluorescence imaging and optical coherence
514 tomography (OCT) was performed.


515 **Generation of *in vivo* reporter constructs and functional characterization of candidate *cis*-**
516 **regulatory UCNE upstream of *PAX6* using enhancer assays in zebrafish embryos**

517 Primers were designed to amplify the sequence of the candidate *cis*-regulatory UCNE located upstream
518 of *PAX6* from human genomic DNA (Roche). The PCR product was then cloned into the E1b-GFP-Tol2
519 enhancer assay vector containing an E1b minimal promoter followed by the Green Fluorescent Protein
520 (GFP) reporter gene (Q. Li et al., 2010) by restriction-ligation cloning. The primer sequences can be
521 found in Supplementary Table 12. The recombinant vector containing the cCRE-*PAX6*-UCNE was then
522 amplified in One Shot TOP10 Chemically Competent *E. coli* cells (Invitrogen) and purified using the
523 QIAprep Spin Miniprep Kit (Qiagen). Additionally, a construct containing the ultra-rare SNV identified
524 in the affected individuals of the family described above was created using the Q5 Site-Directed
525 Mutagenesis Kit (NEB) using variant-specific primers designed with the NEBaseChanger tool. The
526 sequence of the insert was confirmed by Sanger sequencing using the BigDye Terminator v3.1 kit (Life
527 Technologies). The constructs were then microinjected into the yolk of at least 70 wild-type zebrafish
528 embryos at single-cell stage using the Tol2 transposase system for germline integration of the
529 transgene according to Bessa *et al.* (Bessa et al., 2009) with minor modifications. As readout, GFP
530 fluorescence was observed and photographed with a Leica M165 FC Fluorescent Stereo Microscope
531 (Leica Microsystems) and its localization annotated at 1, 2 and 3 days post fertilization (dpf) to evaluate
532 enhancer activity.


533

534


A Annotation of ultraconserved non-coding regions acting as candidate *cis*-regulatory elements




B




C




D




E



F



536 **Figure 1. Integration of publicly available datasets for the characterization of the ultraconserved**
537 **non-coding elements (UCNEs) library. A)** Overview of the integrative multi-omics analysis for the
538 prediction of UCNEs with potential *cis*-regulatory role in human retina. **B)** Venn diagrams illustrating
539 the CREs displaying open chromatin features based on scATAC-seq and DNase-seq (left) and their
540 overlap of active enhancer marks (H3K27ac, H3K4me1 and H3K4me2). **C)** Barplot showing the
541 proportions of elements from the VISTA enhancer browser (V), UCNEs (U), and putative regulatory
542 UCNEs (characterized by retinal datasets) (U⁺) displaying reporter expression (positive). **D)**
543 Proportional stacked barplot showing the distribution of tissues (eye, forebrain, hindbrain, midbrain,
544 neural tube, limb and tail) in which the putative regulatory UCNEs display reporter expression. **E-F)**
545 Illustration of one of the characterized UCNEs (NR2F1_Hector_1/2) displaying open chromatin
546 supported by DNase-seq (embryonic day 74-85, 89 and 103-125) and scATAC-seq (AC/HC/GC
547 Precursors Cells, Early Progenitor Cells, Ganglion Precursor Cells, Late Retinal Progenitor Cells) and
548 enhancer reporter expression in the eye. Figures obtained from VISTA (hs1170) enhancer (E) and UCSC
549 genome (F) browsers. Abbreviations: FW: fetal weeks; V: VISTA enhancer elements; U: UCNEs; U⁺:
550 Putative active regulatory UCNE; ∩: intersection.




551

552


553 **Figure 2. Target genes under putative regulation of characterized UCNEs in retina. A)** Bar plot showing
 554 the number of associated genes per retinal UCNE. **B)** Distance distribution from the TSS and its
 555 associated UCNE. **C)** Gene ontology for the UCNE-associated target genes. Abbreviations: GO: Gene
 556 Ontology; TSS: transcription start site.

A


Mining of variants within candidate *cis*-regulatory UCNEs in WGS data of a rare eye disease cohort



B




C




557

558 **Figure 3. Contribution of UCNE genomic variation to missing heritability in rare eye diseases. A)**
 559 Overview of a sub-cohort comprising n=3,220 participants of the 100,000 Genomes Project affected
 560 by posterior segment abnormalities (n=2,615), anterior segment abnormalities (n=360), and ocular
 561 malformations (n=245). **B)** Variant population frequencies within putative retinal UCNEs normalized to
 562 a background composed of randomly selected sequences (*see Methods*). **C)** Significantly lower
 563 genome-wide residual variation score (gwRVIS) values scores are observed across UCNEs and their
 564 flanking regions compared to the background composed randomly selected sequences, thereby
 565 showing the high intolerance to variation of UCNEs.



566

567 **Figure 4. Characterization of the *cis*-regulatory landscape of *PAX6* in human retina. A)** Visualization
 568 of the epigenomic context of the identified *PAX6*-associated UCNE (highlighted in gray) in relation to
 569 the *PAX6* locus (*top*; chr11:31,490,261-32,075,591) and **B)** Zoomed-in of the identified element
 570 (*bottom*; chr11:31,965,000-31,972,000). Figures are obtained from the UCSC genome browser.



571

572

573 **Figure 5. *In vivo* evaluation of the *PAX6*-associated UCNE. A)** This UCNE displays reporter activity in
574 the human embryonic forebrain (6/9 embryos) as well as in other structures including eye (3/6
575 embryos) and neural tube. Figure obtained from the VISTA enhancer browser (hs855). **B)** Zebrafish
576 enhancer assays at 3 different time points (1 dpf, 2 dpf, 3 dpf) showing GFP-positive tissues (optic
577 fissure -1 dpf-, lens cells -2,3 dpf- and forebrain -2,3 dpf-; *white arrows*). Abbreviations. dpf: days post-
578 fertilization.

579

580

581

582

583

584

585

586

587

588

589

590

591 **COMPETING INTEREST STATEMENT**

592 The authors declare that they have no competing interests.

593 **FUNDING**

594 This work was supported by the Ghent University Special Research Fund (BOF20/GOA/023) (EDB);
595 H2020 MSCA ITN grant (No. 813490 StarT) (EDB, FC, MB), EJPRD19-234 Solve-RET (EDB). EDB is a Senior
596 Clinical Investigator (1802220N) of the Research Foundation-Flanders (FWO); VLS and ADR are an Early
597 Starting Researcher of StarT (grant No. 813490). EDB is member of ERN-EYE (Framework Partnership
598 Agreement No 739534-ERN-EYE).

599 **ACKNOWLEDGEMENTS**

600 This research was made possible through access to the data and findings generated by the 100,000
601 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly
602 owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded
603 by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research
604 UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes
605 Project uses data provided by patients and collected by the National Health Service as part of their
606 care and support. We acknowledge Chris Inglehearn (Leeds Institute of Medical Research, School of
607 Medicine, University of Leeds, Leeds, UK) for his helpful advice and comments for the manuscript. We
608 also would like to thank the Zebrafish Facility Ghent (ZFG) Core at Ghent University. Hanna De Saffel,
609 Quinten Mahieu, Angelika Jürgens and Lies Vantomme are thanked for their excellent technical
610 assistance.

611 **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

612 The 100,000 Genomes Project Protocol has ethical approval from the HRA Committee East of England
613 – Cambridge South (REC Ref 14/EE/1112). This study was registered with Genomics England under
614 Research Registry Projects 465.

615 **AUTHORS' CONTRIBUTIONS**

616 V.L.S.: Conception and project design, acquisition of data, analysis and interpretation of data, drafting
617 and revising the manuscript.

618 A.D.R.: Conception and project design, acquisition of data, analysis and interpretation of data, drafting
619 and revising the manuscript.

620 R.M: Acquisition of data, analysis and interpretation of data, revising the manuscript.

621 G.E: Acquisition of data, revising the manuscript.

622 F.C: Acquisition of data, revising the manuscript.

623 M.B: Project supervision, acquisition of data, revising the manuscript.

624 A.W: Acquisition of data, analysis and interpretation of data, revising the manuscript.

625 E.D.B.: Conception and project supervision, acquisition of data, analysis and interpretation of data,
626 drafting and revising the manuscript.

627 **CONSENT FOR PUBLICATION**

628 Not applicable. We present only de-identified data.

629 **AVAILABILITY OF DATA AND MATERIALS**

630 The data that support the findings of this study are available within the Genomics England (protected)
631 Research Environment but restrictions apply to the availability of these data, as access to the Research
632 Environment is limited to protect the privacy and confidentiality of participants. De-identified data as
633 well as analysis scripts are, however, available from the authors upon reasonable request. Extended
634 data generated in this study are available in the supplementary materials.

635 REFERENCES

- 636 Abascal, F., Acosta, R., Addleman, N. J., Adrian, J., Afzal, V., Aken, B., Akiyama, J. A., Jammal, O. Al, ...
637 Zimmerman, J. (2020). Expanded encyclopaedias of DNA elements in the human and mouse
638 genomes. *Nature*, *583*(7818), 699–710. <https://doi.org/10.1038/s41586-020-2493-4>
- 639 Ahituv, N., Zhu, Y., Visel, A., Holt, A., Afzal, V., Pennacchio, L. A., & Rubin, E. M. (2007). Deletion of
640 ultraconserved elements yields viable mice. *PLoS Biology*, *5*(9), 1906–1911.
641 <https://doi.org/10.1371/journal.pbio.0050234>
- 642 Aldiri, I., Xu, B., Wang, L., Chen, X., Hiler, D., Griffiths, L., Valentine, M., Shirinifard, A., ... Dyer, M. A.
643 (2017). The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming,
644 and Tumorigenesis. *Neuron*, *94*(3), 550-568.e10. <https://doi.org/10.1016/j.neuron.2017.04.022>
- 645 Ashery-Padan, R., Marquardt, T., Zhou, X., & Gruss, P. (2000). Pax6 activity in the lens primordium is
646 required for lens formation and for correct placement of a single retina in the eye. *Genes and*
647 *Development*, *14*(21), 2701–2711. <https://doi.org/10.1101/gad.184000>
- 648 Bejerano, G., Pheasant, M., Makunin, I., Stephen, S., Kent, W. J., Mattick, J. S., & Haussler, D. (2004).
649 Ultraconserved elements in the human genome. *Science*, *304*(5675), 1321–1325.
650 <https://doi.org/10.1126/science.1098119>
- 651 Benko, S., Fantes, J. A., Amiel, J., Kleinjan, D. J., Thomas, S., Ramsay, J., Jamshidi, N., Essafi, A., ...
652 Lyonnet, S. (2009). Highly conserved non-coding elements on either side of SOX9 associated
653 with Pierre Robin sequence. *Nature Genetics*, *41*(3), 359–364. <https://doi.org/10.1038/ng.329>
- 654 Bessa, J., Tena, J. J., De La Calle-Mustienes, E., Fernández-Miñán, A., Naranjo, S., Fernández, A.,
655 Montoliu, L., Akalin, A., ... Gómez-Skarmeta, J. L. (2009). Zebrafish Enhancer Detection (ZED)
656 vector: A new tool to facilitate transgenesis and the functional analysis of cis-regulatory regions
657 in zebrafish. *Developmental Dynamics*, *238*(9), 2409–2417. <https://doi.org/10.1002/dvdy.22051>
- 658 Bhatia, S., Bengani, H., Fish, M., Brown, A., Divizia, M. T., De Marco, R., Damante, G., Grainger, R., ...
659 Kleinjan, D. A. (2013). Disruption of autoregulatory feedback by a mutation in a remote,
660 ultraconserved PAX6 enhancer causes aniridia. *American Journal of Human Genetics*, *93*(6),
661 1126–1134. <https://doi.org/10.1016/j.ajhg.2013.10.028>
- 662 Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016). Near-optimal probabilistic RNA-seq
663 quantification. *Nature Biotechnology*, *34*(5), 525–527. <https://doi.org/10.1038/nbt.3519>
- 664 Cherry, T. J., Yang, M. G., Harmin, D. A., Tao, P., Timms, A. E., Bauwens, M., Allikmets, R., Jones, E. M.,
665 ... Greenberg, M. E. (2020). Mapping the cis-regulatory architecture of the human retina reveals
666 noncoding genetic variation in disease. *Proceedings of the National Academy of Sciences of the*
667 *United States of America*, *117*(16), 9001–9012. <https://doi.org/10.1073/pnas.1922501117>
- 668 Chiang, C. W. K., Derti, A., Schwartz, D., Chou, M. F., Hirschhorn, J. N., & Wu, C. T. (2008).
669 Ultraconserved elements: Analyses of dosage sensitivity, motifs and boundaries. *Genetics*,
670 *180*(4), 2277–2293. <https://doi.org/10.1534/genetics.108.096537>
- 671 Cipriani, V., Silva, R. S., Arno, G., Pontikos, N., Kalhor, A., Valeina, S., Inashkina, I., Audere, M., ...
672 Moore, A. T. (2017). Duplication events downstream of IRX1 cause North Carolina macular
673 dystrophy at the MCDR3 locus. *Scientific Reports*, *7*(1), 1–9. <https://doi.org/10.1038/s41598-017-06387-6>
- 675 Clark, B. S., Stein-O'Brien, G. L., Shiao, F., Cannon, G. H., Davis-Marcisak, E., Sherman, T., Santiago, C.
676 P., Hoang, T. V., ... Blackshaw, S. (2019). Single-Cell RNA-Seq Analysis of Retinal Development
677 Identifies NFI Factors as Regulating Mitotic Exit and Late-Born Cell Specification. *Neuron*, *102*(6),
678 1111-1126.e5. <https://doi.org/10.1016/j.neuron.2019.04.010>

- 679 Collinson, J. M., Quinn, J. C., Hill, R. E., & West, J. D. (2003). The roles of Pax6 in the cornea, retina,
680 and olfactory epithelium of the developing mouse embryo. *Developmental Biology*, 255(2),
681 303–312. [https://doi.org/10.1016/S0012-1606\(02\)00095-7](https://doi.org/10.1016/S0012-1606(02)00095-7)
- 682 Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J.,
683 Lodato, M. A., ... Jaenisch, R. (2010). Histone H3K27ac separates active from poised enhancers
684 and predicts developmental state. *Proceedings of the National Academy of Sciences of the*
685 *United States of America*, 107(50), 21931–21936. <https://doi.org/10.1073/pnas.1016071107>
- 686 Cunha, D. L., Arno, G., Corton, M., & Moosajee, M. (2019). The spectrum of PAX6 mutations and
687 genotype-phenotype correlations in the eye. *Genes*, 10(12).
688 <https://doi.org/10.3390/genes10121050>
- 689 de Bruijn, S. E., Fiorentino, A., Ottaviani, D., Fanucchi, S., Melo, U. S., Corral-Serrano, J. C., Mulders,
690 T., Georgiou, M., ... Hardcastle, A. J. (2020). Structural Variants Create New Topological-
691 Associated Domains and Ectopic Retinal Enhancer-Gene Contact in Dominant Retinitis
692 Pigmentosa. *American Journal of Human Genetics*, 107(5), 802–814.
693 <https://doi.org/10.1016/j.ajhg.2020.09.002>
- 694 Dickel, D. E., Ypsilanti, A. R., Pla, R., Zhu, Y., Barozzi, I., Mannion, B. J., Khin, Y. S., Fukuda-Yuzawa, Y.,
695 ... Visel, A. (2018). Ultraconserved Enhancers Are Required for Normal Development. *Cell*,
696 172(3), 491-499.e15. <https://doi.org/10.1016/j.cell.2017.12.017>
- 697 Dimitrieva, S., & Bucher, P. (2013). UCNEbase - A database of ultraconserved non-coding elements
698 and genomic regulatory blocks. *Nucleic Acids Research*, 41(D1), 101–109.
699 <https://doi.org/10.1093/nar/gks1092>
- 700 Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012). Topological
701 domains in mammalian genomes identified by analysis of chromatin interactions. *Nature*,
702 485(7398), 376–380. <https://doi.org/10.1038/nature11082>
- 703 Drake, J. A., Bird, C., Nemesh, J., Thomas, D. J., Newton-Cheh, C., Reymond, A., Excoffier, L., Attar, H.,
704 ... Hirschhorn, J. N. (2006). Conserved noncoding sequences are selectively constrained and not
705 mutation cold spots. *Nature Genetics*, 38(2), 223–227. <https://doi.org/10.1038/ng1710>
- 706 Dubey, S. K., Mahalaxmi, N., Vijayalakshmi, P., & Sundaresan, P. (2015). Mutational analysis and
707 genotype-phenotype correlations in southern Indian patients with sporadic and familial aniridia.
708 *Molecular Vision*, 21(January), 88–97.
- 709 Dukler, N., Mughal, M. R., Ramani, R., Huang, Y. F., & Siepel, A. (2022). Extreme purifying selection
710 against point mutations in the human genome. *Nature Communications*, 13(1).
711 <https://doi.org/10.1038/s41467-022-31872-6>
- 712 Dunham, I., Kundaje, A., Aldred, S. F., Collins, P. J., Davis, C. A., Doyle, F., Epstein, C. B., Fritze, S., ...
713 Lochovsky, L. (2012). An integrated encyclopedia of DNA elements in the human genome.
714 *Nature*, 489(7414), 57–74. <https://doi.org/10.1038/nature11247>
- 715 Ehrenberg, M., Bagdonite-Bejarano, L., Fulton, A. B., Orenstein, N., & Yahalom, C. (2021). Genetic
716 causes of nystagmus, foveal hypoplasia and subnormal visual acuity- other than albinism.
717 *Ophthalmic Genetics*, 42(3), 243–251. <https://doi.org/10.1080/13816810.2021.1888128>
- 718 Ellingford, J. M., Barton, S., Bhaskar, S., O'Sullivan, J., Williams, S. G., Lamb, J. A., Panda, B.,
719 Sergouniotis, P. I., ... Black, G. C. M. (2016). Molecular findings from 537 individuals with
720 inherited retinal disease. *Journal of Medical Genetics*, 53(11), 761–767.
721 <https://doi.org/10.1136/jmedgenet-2016-103837>
- 722 Engström, P. G., Fredman, D., & Lenhard, B. (2008). Ancora: A web resource for exploring highly

- 723 conserved noncoding elements and their association with developmental regulatory genes.
724 *Genome Biology*, 9(2), 8–11. <https://doi.org/10.1186/gb-2008-9-2-r34>
- 725 Field, A., & Adelman, K. (2020). Evaluating Enhancer Function and Transcription. *Annual Review of*
726 *Biochemistry*, 89, 213–234. <https://doi.org/10.1146/annurev-biochem-011420-095916>
- 727 Georgala, P. A., Carr, C. B., & Price, D. J. (2011). The role of Pax6 in forebrain development.
728 *Developmental Neurobiology*, 71(8), 690–709. <https://doi.org/10.1002/dneu.20895>
- 729 Ghiasvand, N. M., Rudolph, D. D., Mashayekhi, M., Brzezinski, J. A., Goldman, D., & Glaser, T. (2011).
730 Deletion of a remote enhancer near ATOH7 disrupts retinal neurogenesis, causing NCRNA
731 disease. *Nature Neuroscience*, 14(5), 578–588. <https://doi.org/10.1038/nn.2798>
- 732 Goodson, N. B., Nahreini, J., Randazzo, G., Uruena, A., Johnson, J. E., & Brzezinski, J. A. (2018).
733 Prdm13 is required for Ebf3+ amacrine cell formation in the retina. *Developmental Biology*,
734 434(1), 149–163. <https://doi.org/10.1016/j.ydbio.2017.12.003>
- 735 Granja, J. M., Corces, M. R., Pierce, S. E., Bagdatli, S. T., Choudhry, H., Chang, H. Y., & Greenleaf, W. J.
736 (2021). Author Correction: ArchR is a scalable software package for integrative single-cell
737 chromatin accessibility analysis (*Nature Genetics*, (2021), 53, 3, (403-411), 10.1038/s41588-021-
738 00790-6). *Nature Genetics*, 53(6), 935. <https://doi.org/10.1038/s41588-021-00850-x>
- 739 Haer-Wigman, L., Van Zelst-Stams, W. A. G., Pfundt, R., Van Den Born, L. I., Klaver, C. C. W., Verheij, J.
740 B. G. M., Hoyng, C. B., Breuning, M. H., ... Yntema, H. G. (2017). Diagnostic exome sequencing in
741 266 Dutch patients with visual impairment. *European Journal of Human Genetics*, 25(5), 591–
742 599. <https://doi.org/10.1038/ejhg.2017.9>
- 743 Hoshino, A., Ratnapriya, R., Brooks, M. J., Chaitankar, V., Wilken, M. S., Zhang, C., Starostik, M. R.,
744 Gieser, L., ... Reh, T. A. (2017). Molecular Anatomy of the Developing Human Retina.
745 *Developmental Cell*, 43(6), 763–779.e4. <https://doi.org/10.1016/j.devcel.2017.10.029>
- 746 Hussey, K. A., Hadyniak, S. E., & Johnston, R. J. (2022). Patterning and Development of
747 Photoreceptors in the Human Retina. *Frontiers in Cell and Developmental Biology*, 10(April), 1–
748 21. <https://doi.org/10.3389/fcell.2022.878350>
- 749 Juan, A. H., Wang, S., Ko, K. D., Zare, H., Tsai, P. F., Feng, X., Vivanco, K. O., Ascoli, A. M., ... Sartorelli,
750 V. (2016). Roles of H3K27me2 and H3K27me3 Examined during Fate Specification of Embryonic
751 Stem Cells. *Cell Reports*, 17(5), 1369–1382. <https://doi.org/10.1016/j.celrep.2016.09.087>
- 752 Katzman, S., Kern, A. D., Bejerano, G., Fewell, G., Fulton, L., Wilson, R. K., Salama, S. R., & Haussler, D.
753 (2007). Human genome ultraconserved elements are ultraselected. *Science*, 317(5840), 915.
754 <https://doi.org/10.1126/science.1142430>
- 755 Kimura, J., Suda, Y., Kurokawa, D., Hossain, Z. M., Nakamura, M., Takahashi, M., Hara, A., & Aizawa, S.
756 (2005). Emx2 and Pax6 function in cooperation with Otx2 and Otx1 to develop caudal forebrain
757 primordium that includes future archipallium. *Journal of Neuroscience*, 25(21), 5097–5108.
758 <https://doi.org/10.1523/JNEUROSCI.0239-05.2005>
- 759 Klopocki, E., Ott, C. E., Benatar, N., Ullmann, R., Mundlos, S., & Lehmann, K. (2008). A
760 microduplication of the long range SHH limb regulator (ZRS) is associated with triphalangeal
761 thumb-polysyndactyly syndrome. *Journal of Medical Genetics*, 45(6), 370–375.
762 <https://doi.org/10.1136/jmg.2007.055699>
- 763 Kuht, H. J., Han, J., Maconachie, G. D. E., Park, S. E., Lee, S. T., McLean, R., Sheth, V., Hisaund, M., ...
764 Thomas, M. G. (2020). SLC38A8 mutations result in arrested retinal development with loss of
765 cone photoreceptor specialization. *Human Molecular Genetics*, 29(18), 2989–3002.
766 <https://doi.org/10.1093/hmg/ddaa166>

- 767 Kuht, H. J., Maconachie, G. D. E., Han, J., Kessel, L., van Genderen, M. M., McLean, R. J., Hisaund, M.,
768 Tu, Z., ... Thomas, M. G. (2022). Genotypic and Phenotypic Spectrum of Foveal Hypoplasia: A
769 Multicenter Study. *Ophthalmology*, *129*(6), 708–718.
770 <https://doi.org/10.1016/j.ophtha.2022.02.010>
- 771 Kvon, E. Z., Zhu, Y., Kelman, G., Novak, C. S., Plajzer-Frick, I., Kato, M., Garvin, T. H., Pham, Q., ...
772 Pennacchio, L. A. (2020). Comprehensive In Vivo Interrogation Reveals Phenotypic Impact of
773 Human Enhancer Variants. *Cell*, *180*(6), 1262–1271.e15.
774 <https://doi.org/10.1016/j.cell.2020.02.031>
- 775 Larson, M. H., Gilbert, L. A., Wang, X., Lim, W. A., Weissman, J. S., & Qi, L. S. (2013). CRISPR
776 interference (CRISPRi) for sequence-specific control of gene expression. *Nature Protocols*,
777 *8*(11), 2180–2196. <https://doi.org/10.1038/nprot.2013.132>
- 778 Lenassi, E., Carvalho, A., Thormann, A., Fletcher, T., Hardcastle, C., Hunt, S. E., Sergouniotis, P. I.,
779 Michaelides, M., ... Ellingford, J. M. (2021). EyeG2P: an automated variant filtering approach
780 improves efficiency of diagnostic genomic testing for inherited ophthalmic disorders. *MedRxiv*,
781 2021.07.23.21261017.
782 <https://www.medrxiv.org/content/10.1101/2021.07.23.21261017v1%0Ahttps://www.medrxiv.org/content/10.1101/2021.07.23.21261017v1.abstract>
- 784 Lettice, L. A., Heaney, S. J. H., Purdie, L. A., Li, L., de Beer, P., Oostra, B. A., Goode, D., Elgar, G., ... de
785 Graaff, E. (2003). A long-range Shh enhancer regulates expression in the developing limb and fin
786 and is associated with preaxial polydactyly. *Human Molecular Genetics*, *12*(14), 1725–1735.
787 <https://doi.org/10.1093/hmg/ddg180>
- 788 Li, H. (2011). Tabix: Fast retrieval of sequence features from generic TAB-delimited files.
789 *Bioinformatics*, *27*(5), 718–719. <https://doi.org/10.1093/bioinformatics/btq671>
- 790 Li, Q., Ritter, D., Yang, N., Dong, Z., Li, H., Chuang, J. H., & Guo, S. (2010). A systematic approach to
791 identify functional motifs within vertebrate developmental enhancers. *Developmental Biology*,
792 *337*(2), 484–495. <https://doi.org/10.1016/j.ydbio.2009.10.019>
- 793 Lima Cunha, D., Owen, N., Tailor, V., Corton, M., Theodorou, M., & Moosajee, M. (2021). PAX6
794 missense variants in two families with isolated foveal hypoplasia and nystagmus: evidence of
795 paternal postzygotic mosaicism. *European Journal of Human Genetics*, *29*(2), 349–355.
796 <https://doi.org/10.1038/s41431-020-00737-1>
- 797 Lomonaco, V., Martoglia, R., Mandreoli, F., Anderlucci, L., Emmett, W., Bicciato, S., & Taccioli, C.
798 (2014). UCbase 2.0: Ultraconserved sequences database (2014 update). *Database*, *2014*, 1–8.
799 <https://doi.org/10.1093/database/bau062>
- 800 Long, H. K., Osterwalder, M., Welsh, I. C., Hansen, K., Davies, J. O. J., Liu, Y. E., Koska, M., Adams, A.
801 T., ... Wysocka, J. (2020). Loss of Extreme Long-Range Enhancers in Human Neural Crest Drives a
802 Craniofacial Disorder. *Cell Stem Cell*, *27*(5), 765–783.e14.
803 <https://doi.org/10.1016/j.stem.2020.09.001>
- 804 Lupiáñez, D. G., Kraft, K., Heinrich, V., Krawitz, P., Brancati, F., Klopocki, E., Horn, D., Kayserili, H., ...
805 Mundlos, S. (2015). Disruptions of topological chromatin domains cause pathogenic rewiring of
806 gene-enhancer interactions. *Cell*, *161*(5), 1012–1025. <https://doi.org/10.1016/j.cell.2015.04.004>
- 807 Lyu, P., Hoang, T., Santiago, C. P., Thomas, E. D., Timms, A. E., Appel, H., Gimmen, M., Le, N., ...
808 Blackshaw, S. (2021). Gene regulatory networks controlling temporal patterning, neurogenesis,
809 and cell-fate specification in mammalian retina. *Cell Reports*, *37*(7).
810 <https://doi.org/10.1016/j.celrep.2021.109994>

- 811 Marchal, C., Singh, N., Batz, Z., Advani, J., Jaeger, C., Corso-Díaz, X., & Swaroop, A. (2022). High-
812 resolution genome topology of human retina uncovers super enhancer-promoter interactions
813 at tissue-specific and multifactorial disease loci. *Nature Communications*, *13*(1), 1–16.
814 <https://doi.org/10.1038/s41467-022-33427-1>
- 815 Martin, A. R., Williams, E., Foulger, R. E., Leigh, S., Daugherty, L. C., Niblock, O., Leong, I. U. S., Smith,
816 K. R., ... McDonagh, E. M. (2019). PanelApp crowdsources expert knowledge to establish
817 consensus diagnostic gene panels. *Nature Genetics*, *51*(11), 1560–1565.
818 <https://doi.org/10.1038/s41588-019-0528-2>
- 819 Martin, V., Zhao, J., Afek, A., Mielko, Z., & Gordân, R. (2019). QBIC-Pred: Quantitative predictions of
820 transcription factor binding changes due to sequence variants. *Nucleic Acids Research*, *47*(W1),
821 W127–W135. <https://doi.org/10.1093/nar/gkz363>
- 822 Martínez, F., Monfort, S., Rosellá, M., Oltra, S., Blesa, D., Quiroga, R., Mayo, S., & Orellana, C. (2010).
823 Enrichment of ultraconserved elements among genomic imbalances causing mental delay and
824 congenital anomalies. *BMC Medical Genomics*, *3*. <https://doi.org/10.1186/1755-8794-3-54>
- 825 McLean, C. Y., Bristor, D., Hiller, M., Clarke, S. L., Schaar, B. T., Lowe, C. B., Wenger, A. M., &
826 Bejerano, G. (2010). GREAT improves functional interpretation of cis-regulatory regions. *Nature*
827 *Biotechnology*, *28*(5), 495–501. <https://doi.org/10.1038/nbt.1630>
- 828 Morris, A. C., & Fadool, J. M. (2005). Studying rod photoreceptor development in zebrafish.
829 *Physiology and Behavior*, *86*(3), 306–313. <https://doi.org/10.1016/j.physbeh.2005.08.020>
- 830 Pachano, T., Haro, E., & Rada-Iglesias, A. (2022). Enhancer-gene specificity in development and
831 disease. *Development (Cambridge, England)*, *149*(11). <https://doi.org/10.1242/dev.186536>
- 832 Pedersen, H. R., Baraas, R. C., Landsend, E. C. S., Utheim, O. A., Utheim, T. P., Gilson, S. J., & Neitz, M.
833 (2020). PAX6 genotypic and retinal phenotypic characterization in congenital aniridia.
834 *Investigative Ophthalmology and Visual Science*, *61*(5). <https://doi.org/10.1167/IOVS.61.5.14>
- 835 Pennacchio, L. A., Ahituv, N., Moses, A. M., Prabhakar, S., Nobrega, M. A., Shoukry, M., Minovitsky,
836 S., Dubchak, I., ... Rubin, E. M. (2006). In vivo enhancer analysis of human conserved non-coding
837 sequences. *Nature*, *444*(7118), 499–502. <https://doi.org/10.1038/nature05295>
- 838 Pituello, F., Medevielle, F., Foulquier, F., & Duprat, A. M. (1999). Activation of Pax6 depends on
839 somitogenesis in the chick embryo cervical spinal cord. *Development*, *126*(3), 587–596.
840 <https://doi.org/10.1242/dev.126.3.587>
- 841 Plaisancié, J., Tarilonte, M., Ramos, P., Jeanton-Scaramouche, C., Gaston, V., Dollfus, H., Aguilera, D.,
842 Kaplan, J., ... Corton, M. (2018). Implication of non-coding PAX6 mutations in aniridia. *Human*
843 *Genetics*, *137*(10), 831–846. <https://doi.org/10.1007/s00439-018-1940-x>
- 844 Polychronopoulos, D., King, J. W. D., Nash, A. J., Tan, G., & Lenhard, B. (2017). Conserved non-coding
845 elements: Developmental gene regulation meets genome organization. *Nucleic Acids Research*,
846 *45*(22), 12611–12624. <https://doi.org/10.1093/nar/gkx1074>
- 847 Quinlan, A. R., & Hall, I. M. (2010). BEDTools: A flexible suite of utilities for comparing genomic
848 features. *Bioinformatics*, *26*(6), 841–842. <https://doi.org/10.1093/bioinformatics/btq033>
- 849 Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S. A., Flynn, R. A., & Wysocka, J. (2011). A unique
850 chromatin signature uncovers early developmental enhancers in humans. *Nature*, *470*(7333),
851 279–285. <https://doi.org/10.1038/nature09692>
- 852 Rapaport, D. H., Wong, L. L., Wood, E. D., Yasumura, D., & Lavail, M. M. (2004). Timing and
853 topography of cell genesis in the rat retina. *Journal of Comparative Neurology*, *474*(2), 304–324.


- 854 <https://doi.org/10.1002/cne.20134>
- 855 Raychaudhuri, S., Iartchouk, O., Chin, K., Tan, P. L., Tai, A. K., Ripke, S., Gowrisankar, S., Vemuri, S., ...
856 Seddon, J. M. (2011). A rare penetrant mutation in CFH confers high risk of age-related macular
857 degeneration. *Nature Genetics*, *43*(12), 1232–1236. <https://doi.org/10.1038/ng.976>
- 858 Rogers, M. F., Shihab, H. A., Mort, M., Cooper, D. N., Gaunt, T. R., & Campbell, C. (2018). FATHMM-
859 XF: Accurate prediction of pathogenic point mutations via extended features. *Bioinformatics*,
860 *34*(3), 511–513. <https://doi.org/10.1093/bioinformatics/btx536>
- 861 Santana-Garcia, W., Castro-Mondragon, J. A., Padilla-Gálvez, M., Nguyen, N. T. T., Elizondo-Salas, A.,
862 Ksouri, N., Gerbes, F., Thieffry, D., ... Medina-Rivera, A. (2022). RSAT 2022: regulatory sequence
863 analysis tools. *Nucleic Acids Research*, *50*(W1), W670–W676.
864 <https://doi.org/10.1093/nar/gkac312>
- 865 Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C. T., Schreiber, S.
866 L., Mellor, J., & Kouzarides, T. (2002). Active genes are tri-methylated at K4 of histone H3.
867 *Nature*, *419*(6905), 407–411. <https://doi.org/10.1038/nature01080>
- 868 Schmitt, E. A., & Dowling, J. E. (1999). Early retinal development in the Zebrafish, *Danio rerio*: Light
869 and electron microscopic analyses. *Journal of Comparative Neurology*, *404*(4), 515–536.
870 [https://doi.org/10.1002/\(SICI\)1096-9861\(19990222\)404:4<515::AID-CNE8>3.0.CO;2-A](https://doi.org/10.1002/(SICI)1096-9861(19990222)404:4<515::AID-CNE8>3.0.CO;2-A)
- 871 Schwarz, J. M., Hombach, D., Köhler, S., Cooper, D. N., Schuelke, M., & Seelow, D. (2019).
872 RegulationSpotter: Annotation and interpretation of extratranscriptomic DNA variants. *Nucleic*
873 *Acids Research*, *47*(W1), W106–W113. <https://doi.org/10.1093/nar/gkz327>
- 874 Shi, F.-Y., Wang, Y., Huang, D., Liang, Y., Liang, N., Chen, X.-W., & Gao, G. (2021). Computational
875 Assessment of the Expression-modulating Potential for Noncoding Variants. *Genomics,*
876 *Proteomics & Bioinformatics*, *86*. <https://doi.org/10.1016/j.gpb.2021.10.003>
- 877 Small, K. W., DeLuca, A. P., Whitmore, S. S., Rosenberg, T., Silva-Garcia, R., Udar, N., Puech, B., Garcia,
878 C. A., ... Stone, E. M. (2016). North Carolina Macular Dystrophy Is Caused by Dysregulation of
879 the Retinal Transcription Factor PRDM13. *Ophthalmology*, *123*(1), 9–18.
880 <https://doi.org/10.1016/j.ophtha.2015.10.006>
- 881 Smedley, D., Smith, K. R., Martin, A., Thomas, E. A., McDonagh, E. M., Cipriani, V., Ellingford, J. M.,
882 Arno, G., ... Caulfield, M. (2021). 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health
883 Care — Preliminary Report. *New England Journal of Medicine*, *385*(20), 1868–1880.
884 <https://doi.org/10.1056/nejmoa2035790>
- 885 Snetkova, V., Pennacchio, L. A., Visel, A., & Dickel, D. E. (2021). Perfect and imperfect views of
886 ultraconserved sequences. *Nature Reviews Genetics*, *0123456789*.
887 <https://doi.org/10.1038/s41576-021-00424-x>
- 888 Snetkova, V., Ypsilanti, A. R., Akiyama, J. A., Mannion, B. J., Plajzer-Frick, I., Novak, C. S., Harrington,
889 A. N., Pham, Q. T., ... Dickel, D. E. (2021). Ultraconserved enhancer function does not require
890 perfect sequence conservation. *Nature Genetics*, *53*(4), 521–528.
891 <https://doi.org/10.1038/s41588-021-00812-3>
- 892 Sonesson, C., Love, M. I., & Robinson, M. D. (2016). Differential analyses for RNA-seq: Transcript-level
893 estimates improve gene-level inferences. *F1000Research*, *4*, 1–23.
894 <https://doi.org/10.12688/F1000RESEARCH.7563.2>
- 895 Spielmann, M., & Mundlos, S. (2016). Looking beyond the genes: The role of non-coding variants in
896 human disease. *Human Molecular Genetics*, *25*(R2), R157–R165.
897 <https://doi.org/10.1093/hmg/ddw205>

- 898 Taylor, R. L., Poulter, J. A., Downes, S. M., McKibbin, M., Khan, K., Inglehearn, C. F., Webster, A. R.,
899 Hardcastle, A. J., ... van Heyningen, V. (2019). Loss-of-Function Mutations in the CFH Gene
900 Affecting Alternatively Encoded Factor H-like 1 Protein Cause Dominant Early-Onset Macular
901 Drusen. *Ophthalmology*, *126*(10), 1410–1421. <https://doi.org/10.1016/j.ophtha.2019.03.013>
- 902 Thomas, E. D., Timms, A. E., Giles, S., Harkins-Perry, S., Lyu, P., Hoang, T., Qian, J., Jackson, V. E., ...
903 Cherry, T. J. (2022). Cell-specific cis-regulatory elements and mechanisms of non-coding genetic
904 disease in human retina and retinal organoids. *Developmental Cell*, *57*(6), 820-836.e6.
905 <https://doi.org/10.1016/j.devcel.2022.02.018>
- 906 Thormann, A., Halachev, M., McLaren, W., Moore, D. J., Svinti, V., Campbell, A., Kerr, S. M.,
907 Tischkowitz, M., ... FitzPatrick, D. R. (2019). Flexible and scalable diagnostic filtering of genomic
908 variants using G2P with Ensembl VEP. *Nature Communications*, *10*(1), 1–10.
909 <https://doi.org/10.1038/s41467-019-10016-3>
- 910 Turner, D. L., & Cepko, C. L. (1988). A common progenitor for neurons and glia persists in rat retina
911 late in development. *Nature*, *328*(6126), 131–136. <https://doi.org/10.1038/328131a0>
- 912 Turner, D. L., Snyder, E. Y., & Cepko, C. L. (1990). Lineage-independent determination of cell type in
913 the embryonic mouse retina. *Neuron*, *4*(6), 833–845. [https://doi.org/10.1016/0896-](https://doi.org/10.1016/0896-6273(90)90136-4)
914 [6273\(90\)90136-4](https://doi.org/10.1016/0896-6273(90)90136-4)
- 915 Van de Sompele, S., Small, K. W., Cicekdal, M. B., Soriano, V. L., D'haene, E., Shaya, F. S., Agemy, S.,
916 Van der Snickt, T., ... De Baere, E. (2022). Multi-omics approach dissects cis-regulatory
917 mechanisms underlying North Carolina macular dystrophy, a retinal enhanceropathy. *American*
918 *Journal of Human Genetics*, *109*(11), 2029–2048. <https://doi.org/10.1016/j.ajhg.2022.09.013>
- 919 Visel, A., Minovitsky, S., Dubchak, I., & Pennacchio, L. A. (2007). VISTA Enhancer Browser - A database
920 of tissue-specific human enhancers. *Nucleic Acids Research*, *35*(SUPPL. 1), 88–92.
921 <https://doi.org/10.1093/nar/gkl822>
- 922 Vitsios, D., Dhindsa, R. S., Middleton, L., Gussow, A. B., & Petrovski, S. (2021). Prioritizing non-coding
923 regions based on human genomic constraint and sequence context with deep learning. *Nature*
924 *Communications*, *12*(1), 1–14. <https://doi.org/10.1038/s41467-021-21790-4>
- 925 Watanabe, S., Sanuki, R., Sugita, Y., Imai, W., Yamazaki, R., Kozuka, T., Ohsuga, M., & Furukawa, T.
926 (2015). Prdm13 regulates subtype specification of retinal amacrine interneurons and modulates
927 visual sensitivity. *Journal of Neuroscience*, *35*(20), 8004–8020.
928 <https://doi.org/10.1523/JNEUROSCI.0089-15.2015>
- 929 Whittaker, D. E., Oleari, R., Gregory, L. C., Le Quesne-Stabej, P., Williams, H. J., Torpiano, J. G.,
930 Formosa, N., Cachia, M. J., ... Dattani, M. T. (2021). A recessive PRDM13 mutation results in
931 congenital hypogonadotropic hypogonadism and cerebellar hypoplasia. *Journal of Clinical*
932 *Investigation*, *131*(24). <https://doi.org/10.1172/JCI141587>
- 933 Wieczorek, D., Pawlik, B., Li, Y., Akarsu, N. A., Caliebe, A., May, K. J. W., Schweiger, B., Vargas, F. R., ...
934 Wollnik, B. (2010). A specific mutation in the distant sonic hedgehog (SHH) cis-regulator (ZRS)
935 causes Werner Mesomelic Syndrome (WMS) while complete ZRS duplications underlie Haas
936 type polysyndactyly and preaxial polydactyly (PPD) with or without triphalangeal thumb.
937 *Human Mutation*, *31*(1), 81–89. <https://doi.org/10.1002/humu.21142>
- 938 Woolfe, A., Goode, D. K., Cooke, J., Callaway, H., Smith, S., Snell, P., McEwen, G. K., & Elgar, G. (2007).
939 CONDOR: A database resource of developmentally associated conserved non-coding elements.
940 *BMC Developmental Biology*, *7*, 1–11. <https://doi.org/10.1186/1471-213X-7-100>
- 941 Xie, Z., Bailey, A., Kuleshov, M. V., Clarke, D. J. B., Evangelista, J. E., Jenkins, S. L., Lachmann, A.,

- 942 Wojciechowicz, M. L., ... Ma'ayan, A. (2021). Gene Set Knowledge Discovery with Enrichr.
943 *Current Protocols*, 1(3), 1–51. <https://doi.org/10.1002/cpz1.90>
- 944 Yokoi, T., Nishina, S., Fukami, M., Ogata, T., Hosono, K., Hotta, Y., & Azuma, N. (2016). Genotype–
945 phenotype correlation of PAX6 gene mutations in aniridia. *Human Genome Variation*, 3(1), 1–5.
946 <https://doi.org/10.1038/HGV.2015.52>
- 947 Zhang, X., Leavey, P., Appel, H., Makrides, N., & Blackshaw, S. (2023). Molecular mechanisms
948 controlling vertebrate retinal patterning, neurogenesis, and cell fate specification. *Trends in*
949 *Genetics : TIG*, 1–22. <https://doi.org/10.1016/j.tig.2023.06.002>
- 950 Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nussbaum, C., Myers, R.
951 M., ... Shirley, X. S. (2008). Model-based analysis of ChIP-Seq (MACS). *Genome Biology*, 9(9).
952 <https://doi.org/10.1186/gb-2008-9-9-r137>
- 953 Zhou, J., & Troyanskaya, O. G. (2015). Predicting effects of noncoding variants with deep learning-
954 based sequence model. *Nature Methods*, 12(10), 931–934.
955 <https://doi.org/10.1038/nmeth.3547>
- 956

957 **SUPPLEMENTARY MATERIAL**


958



959

960 **Figure S1. Distribution of target genes associated with random genomic background.** To evaluate
961 potential confounding effects of the random genomic background, *GREAT* was used to assign their
962 corresponding target genes. No significant differences were observed in distribution of the number of
963 associated genes (*right*) or distances from transcription start sites (*left*) compared to those of the
964 UCNEs (Fig. 2A-B).

965



966

967 **Figure S2. Allele frequency distribution of disease-associated genes and their respective UCNEs.** For
 968 a selection of 25 disease-associated genes (A) and their corresponding UCNEs (B), allele frequency
 969 distributions were generated to assess the specificity of the overlap between rare variants and UCNEs.


970

971


972

973

A




B




974

975 **Figure S3. *PAX6*-associated variant exclusively found in a family presenting foveal anomalies.** A)
976 Pedigree of the family, indicating segregation of the *PAX6*-associated UCNE variant (V1) and of the *CFH*
977 variant (V2). B) Ophthalmological assessment (fundus examination, FAF, and OCT) revealed tessellated
978 fundi with atrophic areas at the macula involving the fovea in II-1, III-1 and III-2, while I-1 displayed
979 only an area of pallor inferior to the left fovea and corresponding hyper-autofluorescence (see Table
980 S7).

A




B




981

982 **Figure S4. Single-cell characterization of the *PAX6* gene.** A) UMAP of the analyzed single cell dataset
 983 (Thomas et al., 2022). B) Feature plots (scATAC-seq and scRNA-seq) for the *PAX6* locus.



985 **Figure S5. Syntenic region in zebrafish of the human PAX6 locus.** Location of the characterized UCNE
 986 (*in gray, PAX6_Veronica*) linked to PAX6, found exclusively in the *pax6a* locus of zebrafish at a shorter
 987 distance (≈ 15 kb) when compared to the human PAX6 locus (≈ 150 kb) with respect to the PAX6
 988 transcription start site.



989

990 **Figure S6. Peak identification of scATAC-seq and ChIP-seq data. A)** Peak identification within the
 991 *NR2F1* locus for the following marks: H3K4me1, H3K4me2, H3K4me3, CTCF, RNAPolII and H3K27ac
 992 across the different time points.

993 **Table S1. Characterization of UCNEs based on: UCNE ID** – Original UCNE unique identifier from
994 (Dimitrieva et al., 2013); **g.coordinates (hg38)** – genomic coordinate of the UCNE; **Type** – original
995 classification of UCNE (Dimitrieva et al., 2013) based on the genomic location of UCNE with respect to
996 its overlapping gene; **Distance to TSS of target gene** – genomic distance between UCNE and the
997 transcription start site of its target gene (bp); **Target gene** – gene association extracted from GREAT
998 analysis; **Bulk RNA-seq (target gene mean expression)** – expression value (TPM) obtained from the
999 RNA-seq based on samples related to the human retinal development (Hoshino et al., 2018); **Bulk RNA-
1000 seq (target gene expression rank)** – expression rank obtained from the RNA-seq based on samples
1001 related to the human retinal development from (Hoshino et al., 2018); **Bulk RNA-seq (target gene
1002 maximum expression)** – maximum values of gene expression (TPM) obtained from the RNA-seq based
1003 on samples related to the human retinal development (Hoshino et al., 2018); **Bulk RNA-seq (stage of
1004 maximum target gene expression)** – stage where the maximum levels of gene expression were
1005 observed, obtained from the RNA-seq based on samples related to the human retinal development
1006 (Hoshino et al., 2018); **scRNA-seq target gene expression** – retinal cell cluster where the expression of
1007 the target gene is expected, obtained from the scRNA-seq based on samples related to human retinas
1008 (Thomas et al., 2022); **DNase-seq (stage)** – stages where the open chromatin context was identified,
1009 obtained from the DNase-seq experiments related to the retinal development (ENCODE); **scATAC-seq
1010** – cell clusters where the peak identification was retrieved (Thomas et al. 2022); **Retinal TAD Support
1011** – qualitative estimation of the association UCNE-target gene; **ChIP-seq** - epigenomic marks, CTCFs and
1012 PolII peaks observed within the genomic context of the characterized UCNE (Aldiri et al. 2017 , Cherry
1013 et al. 2020); **VISTA (Element ID)** – assessment of the inclusion of the UCNE element within the VISTA
1014 enhancer browser and its unique ID; **VISTA (Assay result)** – reporter assay result from the VISTA
1015 enhancer browser; **VISTA (Expression pattern)** – includes the tissues where the expression pattern for
1016 the reporter assay was observed.

1017 **Table S2. Characterization of UCNEs based on epigenomic marks.**

1018 **Table S3. Full gene set ontology enrichment results from *Enrichr*.**

1019 **Table S4. Comparison between target genes assigned by *GREAT* and peak-to-gene linkage method.**

1020 **Table S5. Disease association of UCNE target genes.** #OMIM disease name; confidence category;
1021 allelic requirement; mutation consequence; phenotypes; organ specificity list; PMIDs. Additional
1022 genomic and functional annotations are the same as in Table S1.

1023 **Table S6. Overview of the eye disease sub-cohort of 100,000 Genomes Project (Genomics England).**
1024 Normalized Disease Group, sub group, and specific disease; Participant Count.

1025 **Table S7. Variants retrieved within the UCNEs that are linked to an eye or retinal disease phenotype.**
1026 It includes the **gene**, the **UCNE ID** and its **coordinates**, and the retrieved **variant** (hg38).

1027 **Table S8. Phenotypic description of the studied family segregating autosomal dominant foveal
1028 abnormalities.** **Participant information** (ID, origin and sex), **molecular findings** (carriers of the V1
1029 (chr11:31968001T>C) and/or V2 (CFH, c.1187A>G (p.Asn396Ser)), **diagnosis** and **age of onset** (Clinical
1030 diagnosis, Age at diagnosis, Age of onset visual field loss, Age of onset BCVA loss) and **clinical findings**.

1031 **Table S9. Analysis of the TFBS motif disruption potentially exerted by the chr11:31968001T>C variant
1032 (qBiC-PRED) and retrieved variants within genes associated with macular developmental defects and
1033 foveal hypoplasia (*IRX1*, *PRMD13*, *SLC38A8*, *GPR143*, *FRMD7* and *AHR*).** Output from qBiC-PRED
1034 includes the predicted TF binding changes, associated name in protein binding microarray experiments
1035 (pbmname), the normalized changes (z-scores), the significance of the changes according to each
1036 model (p.value), and the predicted changes in binding status (e.g. bound > unbound).

1037 **Table S10. Overview of the transgenic enhancer assays in zebrafish for the *PAX6*-associated UCNE.**

1038 **Table S11. Overview of the datasets used in this study.**

1039 **Table S12. Set of primers used in this study for cloning and segregation.**